Procyrion Continues to Expand Adding Operations Manager


HOUSTON, TX (December 06, 2016) - The Houston-based developer of a novel circulatory assist device intended to treat chronic heart failure, Procyrion, Inc., announced today it has added a key team member as it continues its path towards commercialization. James Toll has joined the Procyrion team as Operations Manager.

In his new role as operations manager, Toll, an experienced entrepreneur with a financial background, will help manage day-to-day operations and provide accounting and finance support. He will work closely with Procyrion COO, Jace Heuring to facilitate purchasing, AP/AR, and inventory management; and to ensure all aspects of internal operations run smoothly and efficiently.

“As we get closer to the clinic, we continue to grow and have a lot of moving parts,” said Procyrion CEO Benjamin A. Hertzog, PhD. “There is a lot to balance and James will play a key role to help ensure that things run smoothly.  Additionally, his financial background will be crucial in supporting our rapidly expanding accounting and finance needs.”

Most recently, Toll founded an investment advisory company, developed a family of alternative indexing products, and provided option education services. Previously, Toll engaged in proprietary derivatives trading, was a Director of OTC Trading at Mercury Trading, a member of the Chicago Board Options Exchange, and a member of the CBOE's Product Development Committee. Toll received his BA in Economics from Trinity University in San Antonio, TX.


Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use.  The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients.  For more information, visit or call 713.579.9227.

Dana Summers

Read More